Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in Dry Eye Disease Following Anti-inflammatory Treatment
NCT07025811Phase 4Completed
- Sponsor
- Roche
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cyclosporine ophthalmic solution and lifitegrast in dry eye disease (DED) (3 arms), sponsored by Roche. Primary endpoint: Change From Baseline in Corneal Staining as Measured by Sodium Fluorescein at 12 weeks. Started Jul 2025; status: completed.
02
Drugs
cyclosporine ophthalmic solutionlifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07025811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025811.